$SVA Balance Sheet | Understand Stock

$SVA

$6.47 +$0.00 (0.0%) Close

$SVA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q4 FY2025 As of Dec 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q4 FY2017 As of Dec 31, 2017	Q4 FY2016 As of Dec 31, 2016	Q4 FY2015 As of Dec 31, 2015	Q4 FY2014 As of Dec 31, 2014	Q4 FY2013 As of Dec 31, 2013	Q4 FY2011 As of Dec 31, 2011
ASSETS
Current assets
Cash and cash equivalents
Restricted Cash
Short-term investments
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Deferred tax assets (note 10)
Deferred tax assets (note 14)
Current assets held for sale (note 4)
Income tax receivable
Amounts due from related parties
Total current assets

Property, plant and equipment
Prepaid land lease payments
Intangible assets - net (note 9)
Intangible assets - net
Long-term prepaid expenses
Long-term investments
Prepayments for acquisition of equipment
Deferred tax assets (note 13)
Licenses (note 10)
Long-term assets held for sale (note 3)
Deferred tax assets
Operating lease right-of-use assets
Long–term inventories
Other non-current assets
Deferred tax assets (note 10)
Licenses and permits (note 8)
Goodwill
Amounts due from related parties
Total non-current assets
Total assets

LIABILITIES AND EQUITY
Current liabilities
Loans payable (note 9)
Short-term bank loans (note 10)
Short-term bank loans and current portion of long-term bank loans (note 13)
Loan from a non-controlling shareholder (note 11 (a))
Accounts payable and accrued liabilities
Income tax payable
Deferred revenue (note 20)
Deferred revenue, current
Deferred government grants, current
Current liabilities held for sale (note 4)
Dividend payable
Deferred government grants (note 19)
Operating lease liabilities, current
Amounts due to related parties
Total current liabilities

Deferred government grants, non-current
Long-term bank loans
Deferred tax liabilities
Loan from a non-controlling shareholder (note 13 (a))
Loan from a non-controlling shareholder
Operating lease liabilities, non-current
Other non-current liabilities
Long-term liabilities held for sale (note 3)
Deferred revenue
Total long-term liabilities
Total liabilities
EQUITY
Preferred stock (note 20) Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: 14,630,813, including 14,630,813 held in trust (2023 - 14,630,813, 14,630,813)
Common stock ($0.001 par value; 100,000,000 shares authorized; 71,860,702 and 71,860,702 shares issued and outstanding as of December 31, 2025 and 2024, respectively)
Additional paid-in capital
Subscriptions receivable
Accumulated other comprehensive loss
Statutory surplus reserves (note 18)
Accumulated deficit
Statutory surplus reserves
Retained earnings
Total Sinovac shareholders' equity
Non-controlling interests
Total equity

Total liabilities and equity

Comments